Our company
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical needs.
Our drug Candidates
Two drug candidates are currently in clinical development: PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A and PXT864 for Alzheimerโs disease. Both of our lead assets originated from the Pleotherapy R&D approach.
2007
Served areaWorldwide
Headcount44
Headquarters46 Rue Saint Lazare, 75009 Paris โ France
314,984,176
IPOJuly 18, 2016
Stock exchange(s)Euronext Paris